RPH-104 ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
266家族性地中海熱2

266. 家族性地中海熱

臨床試験数 : 28 /  薬物数 : 22 - (DrugBank : 5) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 59
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05190991
(ClinicalTrials.gov)		October 5, 20213/11/2021Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean FeverAn International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineFamilial Mediterranean Fever;FMFBiological: RPH-104R-Pharm International, LLCAtlant Clinical LLC;Center for Pharmaceutical Analytics LLC;Unimed Laboratories CJSC;Data Management 365Recruiting18 Years80 YearsAll60Phase 2Armenia;Georgia;Russian Federation
2NCT05092776
(ClinicalTrials.gov)		April 29, 20219/9/2021Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineInternational, Multicenter, Double Blind, Placebo-controlled, Randomized Clinical Study of Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineFamilial Mediterranean Fever;FMFBiological: RPH-104;Drug: PlaceboR-Pharm International, LLCData Management 365;Atlant Clinical LLC;R-Pharm;Center of Pharmaceutical Analytics LLC;Unimed Laboratories CJSCRecruiting18 YearsN/AAll60Phase 2Armenia;Georgia;Russian Federation